Beam Therapeutics Inc. reported $156M of revenue over the trailing twelve months, +159% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $156M (to Q2 2026). Net income: −$85M, trailing twelve months to Q2 2026. Free cash flow: −$373M, trailing twelve months to Q2 2026. Operating margin: −6872%, trailing twelve months to Q2 2026.

BEAMBeam Therapeutics Inc.

Healthcare

$25.71+5.7% 1Y

$25.71

$20.6052 weeks$35.53

BEAM as reported

Beam Therapeutics Inc. reported $156M of revenue over the trailing twelve months, +159% on the year before. 8 reported series are charted on this page, each one as filed.

$156M

Revenue, trailing twelve months · to Q2 2026 · +159% against the twelve months before

Net income: −$85M
Net income · −79% year on year · trailing twelve months to Q2 2026
Free cash flow: −$373M
Free cash flow · +4.8% year on year · trailing twelve months to Q2 2026
Operating margin: −6872%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BEAM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$156M	+159%	Q2 2026
Net income	−$85M	−79%	Q2 2026
EPS	−$0.68	−85%	Q2 2026
Operating margin	−6872%	n/a	Q2 2026
Net margin	−6570%	n/a	Q2 2026
ROE	−16%	n/a	Q2 2026
ROA	−12%	n/a	Q2 2026
Free cash flow	−$373M	+4.8%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.